Radioisotopes for metastatic bone pain

Area of Science:

• Oncology
• Nuclear Medicine
• Palliative Care

Background:

• Bone metastases cause severe pain, pathological fractures, and other complications.
• Current treatments for bone metastasis pain include analgesia, radiotherapy, surgery, chemotherapy, hormone therapy, radioisotopes, and bisphosphonates.

Purpose of the Study:

• To evaluate the efficacy and safety of radioisotopes in managing metastatic bone pain.
• To assess the impact of radioisotopes on reducing complications and improving survival in patients with bone metastases.

Main Methods:

• A systematic review of randomized controlled trials (RCTs) was conducted, searching databases including MEDLINE, EMBASE, and CENTRAL up to October 2010.
• Studies included patients with metastatic bone pain treated with radioisotopes compared to placebo or other radioisotopes.
• Risk of bias was assessed, and data were analyzed using random-effects models with intention-to-treat sensitivity analysis.

Main Results:

• Radioisotopes showed a small benefit in complete pain relief (NNT=5) and complete/partial relief (NNT=4) in the short to medium term.
• No conclusive evidence was found that radioisotopes reduce the need for analgesics compared to placebo.
• Significant adverse effects, including leucocytopenia and thrombocytopenia (NNH=13), were associated with radioisotope administration.

Conclusions:

• Radioisotopes may offer pain reduction for bone metastases over one to six months without increasing analgesic use.
• However, severe adverse effects such as leucocytopenia and thrombocytopenia are common.
• Limited data exist for comparing different radioisotopes (e.g., Strontium-89 vs. Samarium-153) and doses.